Is GenScript Biotech profitable in 2025?

Yes. GenScript reported FY2025 revenue of approximately US$959.5 million (up 61.4% YoY) and adjusted net profit of US$230.3 million, up sharply from US$59.8 million in FY2024, per its March 16, 2026 results announcement.

Could AI replace GenScript's gene synthesis business?

Unlikely soon. AI protein-design tools like EvolutionaryScale's ESM3 (Feb 2025) and Latent Labs' Latent-X2 (Jan 2026) used GenScript as their wet-lab validation partner, feeding demand for physical synthesis rather than replacing it.

Who owns GenScript Biotech and is it state-controlled?

GenScript is a publicly traded company on the Hong Kong Stock Exchange (1548.HK) since 2015, founded in 2002 in New Jersey. In May 2024 the House Select Committee on the CCP requested an FBI/DNI briefing on possible undue Chinese government influence over it.

Who is GenScript Biotech's biggest competitor?

In gene synthesis, Thermo Fisher (GeneArt), Danaher's IDT, and Twist Bioscience compete on cost and speed. In biologics CDMO, GenScript's ProBio unit competes against the much larger WuXi Biologics, which faces the same US regulatory scrutiny as of 2026.

Will GenScript be banned from US government contracts?

Not yet as of July 2026, but risk is rising: the BIOSECURE Act became law December 18, 2025, and Congress explicitly named GenScript Group in a December 2025 letter urging DoD to add it to the 1260H restricted list.

Is GenScript's 2025 revenue growth sustainable?

Partly. Much of the 61.4% FY2025 revenue jump came from a one-off ProBio licensing payment of about US$283.6 million after tax tied to LaNova Medicines (disclosed October 14, 2025), while core Life Science Group revenue grew a steadier 14.8% YoY.

Biotech tools companies · China

GenScript Biotech

genscript.com ↗

Chinese gene-synthesis and biologics CDMO serving 200k+ customers worldwide.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from mid-2026 · Every call on the record Checkpoint: DoD/OMB decision on whether to name GenScript, Legend, or ProBio to the 1260H restricted list; BINSA outbound-investment rules also loom

The call

The lab business runs on real infrastructure and sticky customers, but a US restricted-entity listing, not a rival product, is the event that would actually change the picture.

GenScript Biotech sells custom DNA strands and provides manufacturing services for biologics companies worldwide. It has built a hard-to-copy operation through massive scale, automation, and certifications that took years to establish, plus a customer base of over 200,000 companies across more than 100 countries. AI design tools like those from Amazon and others actually help GenScript by creating more demand for its lab work (these tools design proteins but still need real-world testing). However, the U.S. Congress and Pentagon have flagged GenScript as a potential restricted company, which could block its licensing revenue and upend its profitability. Whether the company survives as a profitable business now depends less on competitors or technology and more on whether American regulators impose legal restrictions.

Why

AI pressure: EvolutionaryScale ESM3, Latent Labs Latent-X2, Amazon Bio Discovery. AI protein-design tools generate more sequences to synthesize and test, sending GenScript more orders, not fewer. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher (GeneArt), Danaher (IDT), Twist Bioscience, WuXi Biologics. All compete directly in gene synthesis or biologics CDMO today, but none is visibly pulling customers away from GenScript yet. Could a giant copy it? Yes, easily.

What protects it. Global GMP manufacturing scale, automation, and 200,000+ customers across 100+ countries built up over years.

What would change this call

DoD or OMB names GenScript, Legend, or ProBio on the 1260H or BIOSECURE restricted list. Would confirm the geopolitical moat threat is materializing, not hypothetical.
BINSA outbound-investment restrictions enacted into law around mid-2026. Would show US legally constraining GenScript's licensing-revenue and JV financing model.
GenScript reports FY2026 organic LSG revenue growth ex-LaNova and any Top-20 pharma renewal announcements. Would show whether core demand and pharma customer confidence hold without one-off licensing windfalls.

Key numbers

FY2025 group revenue $959.5M, up 61.4% YoY (2026-03-16)
ProBio CDMO revenue $388.7M, up 309.1% YoY (2026-03-16)
ProBio got ~$283.6M after-tax from one LaNova license deal (2025-10-14)

Named risks

Congress named GenScript Group in Dec 2025 letter urging DoD 1260H restricted-list expansion. Severity: high
BINSA bill (June 2026) could restrict biotech licensing/JV deals central to GenScript's revenue model. Severity: high
FY2025 growth heavily reliant on one-off ~$283.6M LaNova license payment, not recurring CDMO revenue. Severity: medium
Stock volatility with 52-week range of roughly HK$9.45 to HK$19.40 tied to geopolitical headlines. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher (GeneArt)	contesting	Competes directly in gene synthesis on cost and speed as of 2025
Danaher (IDT)	contesting	Direct gene-synthesis rival, structurally able but not actively taking share, 2025
Twist Bioscience	contesting	Named direct gene-synthesis competitor in industry market reports, 2025
WuXi Biologics	contesting	Both face same BIOSECURE/1260H regulatory pressure as of mid-2026, per ainvest.com July 2026

Questions people ask

Is GenScript Biotech profitable in 2025?: Yes. GenScript reported FY2025 revenue of approximately US$959.5 million (up 61.4% YoY) and adjusted net profit of US$230.3 million, up sharply from US$59.8 million in FY2024, per its March 16, 2026 results announcement.
Could AI replace GenScript's gene synthesis business?: Unlikely soon. AI protein-design tools like EvolutionaryScale's ESM3 (Feb 2025) and Latent Labs' Latent-X2 (Jan 2026) used GenScript as their wet-lab validation partner, feeding demand for physical synthesis rather than replacing it.
Who owns GenScript Biotech and is it state-controlled?: GenScript is a publicly traded company on the Hong Kong Stock Exchange (1548.HK) since 2015, founded in 2002 in New Jersey. In May 2024 the House Select Committee on the CCP requested an FBI/DNI briefing on possible undue Chinese government influence over it.
Who is GenScript Biotech's biggest competitor?: In gene synthesis, Thermo Fisher (GeneArt), Danaher's IDT, and Twist Bioscience compete on cost and speed. In biologics CDMO, GenScript's ProBio unit competes against the much larger WuXi Biologics, which faces the same US regulatory scrutiny as of 2026.
Will GenScript be banned from US government contracts?: Not yet as of July 2026, but risk is rising: the BIOSECURE Act became law December 18, 2025, and Congress explicitly named GenScript Group in a December 2025 letter urging DoD to add it to the 1260H restricted list.
Is GenScript's 2025 revenue growth sustainable?: Partly. Much of the 61.4% FY2025 revenue jump came from a one-off ProBio licensing payment of about US$283.6 million after tax tied to LaNova Medicines (disclosed October 14, 2025), while core Life Science Group revenue grew a steadier 14.8% YoY.

Timeline

2026-06-01BINSA bill introduced to extend outbound-investment controls to biotech licensing deals with PRC-linked entities
2026-04-14Legend Biotech reports Q1 2026 CARVYKTI sales of $597M; reclassified as GenScript associate, not subsidiary
2026-04-09GenScript announces Mimulus partnership for DNA-based molecular data-archive infrastructure
2026-03-16GenScript reports FY2025 revenue of $959.5M (+61.4% YoY) and adjusted net profit of $230.3M
2026-01-29GenScript convenes AI/biopharma Global Forum in San Francisco alongside JPM Healthcare Conference
2026-01-28GenScript announces wet-lab validation partnership for Latent Labs' Latent-X2 AI design model
2025-12-18BIOSECURE Act becomes US law under FY26 NDAA, restricting federal deals with Chinese biotech companies of concern
2025-12Congress sends DoD letter naming GenScript Group for 1260H restricted-companies list expansion
2025-10-14ProBio discloses cumulative ~$283.6M after-tax license payments from LaNova Medicines deal
2024-05House Select Committee on CCP requests FBI/DNI briefing on Chinese influence over GenScript

Head to head

GenScript Biotech vs Synthego Corporation

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation